These findings are consistent with our finding that silencing of MIR124-2 and NUS1P3 through promoter methylation in BBM samples may provide a selective advantage for metastasised tumours to survive and to proliferate in the brain microenvironment. The gene discussed is NUS1P3; the disease is neoplasm.